3 assets in Thymus Neoplasm

Therapeutic assets addressing Thymus Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Thymus Neoplasm	National Cancer Institute (NCI)	P1	CC (43)
Fludarabine Thymus Neoplasm	National Cancer Institute (NCI)	P1	CC (43)
Tnhyp217 Car T Cells Thymus Neoplasm	National Cancer Institute (NCI)	P1	CC (43)